Long-term comparison of tacrolimus and cyclosporine-based immunosuppression in kidney recipients with grafts from non-heart-beating cadaver donor.
Kinukawa
T
T
Tokai Urologic Clinical Trial Group, Nagoya, Japan.
Ohshima
S
S
Ono
Y
Y
Fujita
T
T
Hattori
R
R
Tanaka
K
K
D000293:Adolescent; D000328:Adult; D001803:Blood Transfusion; D002102:Cadaver; D016572:Cyclosporine / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000453:epidemiology; D006085:Graft Survival; D006650:Histocompatibility Testing; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology* / Q000401:mortality / Q000502:physiology; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D008875:Middle Aged; D011183:Postoperative Complications / Q000145:classification / Q000453:epidemiology; D011239:Prednisolone / Q000627:therapeutic use; D015996:Survival Rate; D016559:Tacrolimus / Q000627:therapeutic use*; D013997:Time Factors; D014019:Tissue Donors
D007166:Immunosuppressive Agents; D016572:Cyclosporine; D011239:Prednisolone; D016559:Tacrolimus; D008775:Methylprednisolone